Amol Akhade: First T cell therapy for metastatic synovial sarcoma
Amol Akhade shared a post on X:
“FDA approves first T cell therapy for metastatic synovial sarcoma.
Tecelra- Based upon spearhead-1 trial .
Median duration of response 6 months. ORR 37 % . Accelerated approval.
Final approval is subject to further trials.
It is a difficult to treat disease. But this short PFS and response rate may not hold in phase 3 trial. What do u think?”
Source: Amol Akhade/X
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023